All In Biotech

Drug Trial Radar · NCT03378531

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency

An Open-label, Multicentre Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of AEB1102 in Patients With Arginase 1 Deficiency

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

14

Actual

Start

Dec 7, 2017

Primary completion

Dec 15, 2022

Study completion Dec 15, 2022

Sponsor

Lead sponsor
Immedica Pharma ABIndustry
Sponsor type
Industry
Collaborators
Aeglea Biotherapeutics
First posted
Dec 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.

Conditions

  • Arginase I Deficiency
  • Hyperargininemia

Interventions

  • AEB1102Drug

    modified human arginase I

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse EventsTime frame: From start of study up to 262 weeks
  2. Number of Participants With Anti-pegzilarginase and Anti-PEG AntibodiesTime frame: From start of study up to 262 weeks

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Stanford University School of Medicine

    Stanford, California

  • University of Florida

    Gainsville, Florida

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • UTSW

    Dallas, Texas

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • Centro Hospitalar S. Joao

    Porto, Portugal

  • Great Ormond Street Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.